Fresenius Kabi Introduces Copay Assistance for Cancer Treatments Using Generic Medicines

KabiConnect is designed to increase access and lower out-of-pocket costs for eligible patients with financial needs

April 13, 2022

LAKE ZURICH, Ill., April 13, 2022 – Fresenius Kabi announced today it has introduced KabiConnect, part of the KabiCare patient support program in the United States, to offer copay assistance for the company’s generic oncology medicines.  Fresenius Kabi offers the most comprehensive portfolio of generic injectable oncology medicines in the U.S.

KabiConnect offers eligible patients financial support covering more than 30 different oncology medicines. The program can lower out-of-pocket costs to as little as $0 a month for eligible patients. To determine eligibility, patients should speak to their physician. Enrollment is a simple online process. Details can be found on the KabiCare website at

“The cancer journey through diagnosis and treatment can be complex for patients, families and caregivers,” said Tom Tsilipetros, senior director, Market Access, at Fresenius Kabi USA.  “Our goal is help make this a little easier, and to make high-quality medicines more accessible and more affordable to more people. This kind of support can make a huge difference for patients and their families when they need it most.”

“As a leading U.S. developer and supplier of oncology injectable medicines, Fresenius Kabi knows firsthand the value generic medicines play in creating more affordable access to vitally important cancer treatments,” said Pere Berkowitz, vice president, Oncology Marketing, at Fresenius Kabi USA. “The introduction of the KabiConnect Copay Assistance Program extends our continuing commitment to support access to essential medicines for those patients with cancer.” 

The copay assistance program is not available for patients who already receive reimbursement, in whole or in part, by any state or federal health care program.

About KabiCare, a Patient Support Program

Fresenius Kabi created KabiCare, a Patient Support Program, to support patient access to products across numerous therapeutic areas.  KabiCare provides a patient-centric approach which includes support and resources for eligible patients, caregivers, and health care providers throughout the treatment journey.  For eligible patients, support may include navigating complex insurance processes as well as financial assistance.  For additional information, please call 1-833-KABICARE or visit

About Fresenius Kabi

Fresenius Kabi ( is a global health care company that specializes in pharmaceuticals and medical technologies for infusion, transfusion and clinical nutrition. The company’s products and services are used to help care for patients with critical and chronic conditions. The company’s U.S. headquarters is in Lake Zurich, Illinois. The company’s global headquarters is in Bad Homburg, Germany.